R&D News | pharmaphorum

News

Biogen's eye disease gene therapy fails ahead of FDA Alzheim...

Biogen has downbeat news about its gene therapy for the rare inherited eye disease, X-linked retinitis pigmentosa, announcing the shot failed to meet its target in a phase 2/3 study.

News

Talking vaccines: Industry’s role in protecting the Gavi generation

Sanofi/GSK move latecomer COVID-19 shot into phase 3

Sanofi and GlaxoSmithKline seem to be getting somewhere with their COVID-19 vaccine at last, announcing plans to move to phase 3 following supportive mid-stage trial results.

News

Businessmen trading stocks online. Stock brokers looking at graphs, indexes and numbers on multiple computer screens. Colleagues in discussion in traders office. Business success concept.

Arecor hopes London stock market float will raise profile of...

UK biotech Arecor Therapeutics has announced plans to float on the London stock market, to fund plans to develop novel formulations of insulins and other biological drugs with enhanced prop

News

Scepticism in press over Kintor's COVID-19 US drug trial

China’s Kintor Pharmaceutical has begun late-stage US clinical development of its potential COVID drug proxalutamide – but there is scepticism over the company’s claims about its research.<

News

Indian COVID variant puts UK lockdown easing plans in doubt

Concerns are emerging in the UK about the spread of the coronavirus variant that has caused a surge in cases in India, prompting warnings that lockdown easing plans may need a rethink.

News

Biogen taps Envisagenics' AI to speed up RNA splicing R&D

Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets an

Biogen's eye disease gene therapy fails ahead of FDA Alzheim...

Sanofi/GSK move latecomer COVID-19 shot into phase 3

Arecor hopes London stock market float will raise profile of...

Scepticism in press over Kintor's COVID-19 US drug trial

Indian COVID variant puts UK lockdown easing plans in doubt

Biogen taps Envisagenics' AI to speed up RNA splicing R&D

UCB buys cell therapy biotech Candid for $2bn upfront

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks